Signaling-Biased and Constitutively Active Dopamine D2 Receptor Variant

被引:12
|
作者
Rodriguez-Contreras, Dayana [1 ,2 ]
Condon, Alec F. [3 ]
Buck, David C. [4 ]
Asad, Naeem [5 ]
Dore, Timothy M. [5 ]
Verbeek, Dineke S. [6 ,7 ]
Tijssen, Marina A. J. [6 ,8 ]
Shinde, Ujwal [9 ]
Williams, John T. [3 ]
Neve, Kim A. [1 ,2 ]
机构
[1] Oregon Hlth & Sci Univ, VA Portland Hlth Care Syst, Res Serv, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA
[4] VA Portland Hlth Care Syst, Res Serv, Portland, OR 97239 USA
[5] New York Univ Abu Dhabi, Abu Dhabi, U Arab Emirates
[6] Univ Groningen, Expertise Ctr Movement Disorders, NL-9700 AB Groningen, Netherlands
[7] Univ Groningen, Dept Genet, NL-9700 AB Groningen, Netherlands
[8] Univ Groningen, Dept Neurol, NL-9700 AB Groningen, Netherlands
[9] Oregon Hlth & Sci Univ, Dept Chem Physiol & Biochem, Portland, OR 97239 USA
来源
ACS CHEMICAL NEUROSCIENCE | 2021年 / 12卷 / 11期
关键词
Dopamine; D2; receptor; allelic variant; constitutive activity; biased signaling; G protein; arrestin; PROTEIN-COUPLED RECEPTOR; STRUCTURAL INSTABILITY; ADENYLATE-CYCLASE; ACTIVATION; D-2; BINDING; SENSITIZATION; TRAFFICKING; MECHANISMS; MUTATION;
D O I
10.1021/acschemneuro.0c00712
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A dopamine D2 receptor mutation was recently identified in a family with a novel hyperkinetic movement disorder. Compared to the wild type D2 receptor, the novel allelic variant D2-I212F activates a G alpha(i1)beta(1)gamma(2) heterotrimer with higher potency and modestly enhanced basal activity in human embryonic kidney (HEK) 293 cells and has decreased capacity to recruit arrestin3. We now report that omitting overexpressed G protein-coupled receptor kinase-2 (GRK2) decreased the potency and efficacy of quinpirole for arrestin recruitment. The relative efficacy of quinpirole for arrestin recruitment to D2-(IF)-F-212 compared to D2-WT was considerably lower without overexpressed GRK2 than with added GRK2. D2-(IF)-F-212 exhibited higher basal activation of G alpha(oA) than G alpha(i1) but little or no increase in the potency of quinpirole relative to D2-WT. Other signs of D2-(IF)-F-212 constitutive activity for G protein-mediated signaling, in addition to basal activation of G alpha(i/o), were enhanced basal inhibition of forskolin-stimulated cyclic AMP accumulation that was reversed by the inverse agonists sulpiride and spiperone and a similar to 4-fold increase in the apparent affinity of D2-(IF)-F-212 for quinpirole, determined from competition binding assays. In mouse midbrain slices, inhibition of tonic current by the inverse agonist sulpiride in dopamine neurons expressing D2-(IF)-F-212 was consistent with our hypothesis of enhanced constitutive activity and sensitivity to dopamine relative to D2-WT. Molecular dynamics simulations with D2 receptor models suggested that an ionic lock between the cytoplasmic ends of the third and sixth a-helices that constrains many G protein-coupled receptors in an inactive conformation spontaneously breaks in D2-(IF)-F-212. Overall, these results confirm that D2-(IF)-F-212 is a constitutively active and signaling-biased D2 receptor mutant and also suggest that the effect of the likely pathogenic variant in a given brain region will depend on the nature of G protein and GRK expression.
引用
收藏
页码:1873 / 1884
页数:12
相关论文
共 50 条
  • [1] New Concepts in Dopamine D2 Receptor Biased Signaling and Implications for Schizophrenia Therapy
    Urs, Nikhil M.
    Peterson, Sean M.
    Caron, Marc G.
    BIOLOGICAL PSYCHIATRY, 2017, 81 (01) : 78 - 85
  • [2] G Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation
    Namkung, Yoon
    Dipace, Concetta
    Urizar, Eneko
    Javitch, Jonathan A.
    Sibley, David R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (49) : 34103 - 34115
  • [3] Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers
    Borroto-Escuela, Dasiel O.
    Ravani, Annalisa
    Tarakanov, Alexander O.
    Brito, Ismel
    Narvaez, Manuel
    Romero-Fernandez, Wilber
    Corrales, Fidel
    Agnati, Luigi F.
    Tanganelli, Sergio
    Ferraro, Luca
    Fuxe, Kjell
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 435 (01) : 140 - 146
  • [4] Evidence that calmodulin binding to the dopamine D2 receptor enhances receptor signaling
    Liu, Yong
    Buck, David C.
    Macey, Tara A.
    Lan, Hongxiang
    Neve, Kim A.
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2007, 27 (01) : 47 - 65
  • [5] Comparison of the function of two novel human dopamine D2 receptor variants identifies a likely mechanism for their pathogenicity
    Rodriguez-Contreras, Dayana
    Garcia-Nafria, Javier
    Chan, Amy E.
    Shinde, Ujwal
    Neve, Kim A.
    BIOCHEMICAL PHARMACOLOGY, 2024, 228
  • [6] α-Synuclein enhances dopamine D2 receptor signaling
    Kim, Sung Jae
    Kim, Sung Yul
    Na, Young-Soon
    Lee, Hyun Jung
    Chung, Kwang Chul
    Baik, Ja-Hyun
    BRAIN RESEARCH, 2006, 1124 : 5 - 9
  • [7] β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation
    Maennel, Barbara
    Huebner, Harald
    Moeller, Dorothee
    Gmeiner, Peter
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (20) : 5613 - 5628
  • [8] Specific knockdown of the D2 long dopamine receptor variant
    Naughton, Bart J.
    Thirtamara-Rajamani, Keerthi
    Wang, Chuansong
    During, Matthew J.
    Gu, Howard H.
    NEUROREPORT, 2012, 23 (01) : 1 - 5
  • [9] New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling
    Brust, Tarsis F.
    Hayes, Michael P.
    Roman, David L.
    Watts, Val J.
    BIOCHEMICAL PHARMACOLOGY, 2015, 93 (01) : 85 - 91
  • [10] Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation
    Hearst, Scoty M.
    Lopez, Mariper E.
    Shao, Qingmei
    Liu, Yong
    Vig, Parminder J. S.
    JOURNAL OF NEUROCHEMISTRY, 2010, 114 (03) : 706 - 716